Heidelberg and Planegg, Germany, 22 September, 2020 – EMBL Enterprise Management Technology Transfer GmbH (EMBLEM), the technology transfer arm of the European Molecular Biology Laboratory (EMBL), Europe’s flagship laboratory in the life sciences, and PreOmics, a developer of innovative technologies for mass spectrometry-based sample preparation, announced today that they have entered into an exclusive licensing agreement for EMBL’s proprietary SP3 technology, a high-throughput technology for proteomic sample preparation.

The technology was developed in the lab of Jeroen Krijgsveld and within the framework of EMBL’s interdisciplinary postdoctoral program (EIPOD) and allows for ultrasensitive, rapid, unbiased and flexible sample preparation for proteomic analysis.

“We are pleased that the SP3 technology will be made available to a wider user community since the development and transfer of technology for the benefit of society is one of the core missions of the EMBL” says Gábor M. Lamm, Managing Director of EMBLEM. “PreOmics is a perfect partner and their profound expertise in the field will enable the SP3 technology to unfold its full potential.”

SP3 not only overcomes current limitations in proteomics sample preparation such as substantial loss of material, but is also perfectly suited for automation. The technology will complement PreOmics’ streamlined workflows for sample preparation, contributing to bringing increased sample throughput and improved quality for the production of reliable data to customers worldwide. The financial details of the licensing agreement were not disclosed.

“We are very excited to extend our existing iST workflows with the innovative SP3 technology that together now set the standard for protein analysis, and to share this innovation with our highly valued academic and biopharma customers around the world“ says Dr. Garwin Pichler, Managing Director of PreOmics. „We are convinced that the SP3 technology is a perfect complement to our iST sample processing technology as a manual workflow or fully automated on our ultra-efficient PreON platform.”


EMBLEM, established in 1999, identifies, protects and commercializes the intellectual property developed in the EMBL world, from EMBL alumni and from non-EMBL third parties. EMBLEM currently manages a portfolio of more than 400 granted patents and patent applications, and has created more than 20 spin-out companies. EMBLEM facilitates and accelerates the transfer of innovative technology from basic research to industry by working closely with industrial partners spanning the biotech, IT and mechanical/electrical engineering markets and currently has more than 400 licensees of EMBL technologies.

About EMBL

EMBL is Europe’s flagship laboratory for the life sciences. Established in 1974 as an intergovernmental organisation, EMBL is supported by over 20 member states. EMBL performs fundamental research in molecular biology, studying the story of life. The institute offers services to the scientific community; trains the next generation of scientists and strives to integrate the life sciences across Europe.
EMBL is international, innovative and interdisciplinary. Its more than 1600 staff, from over 80 countries, operate across six sites in Barcelona (Spain), Grenoble (France), Hamburg (Germany), Heidelberg (Germany), Hinxton (UK) and Rome (Italy). EMBL scientists work in independent groups and conduct research and offer services in all areas of molecular biology.
EMBL research drives the development of new technology and methods in the life sciences. The institute works to transfer this knowledge for the benefit of society.

For more information, please visit https://www.embl.de

About PreOmics

PreOmics is as a spin-off company from the proteomics research group of pioneer Matthias Mann at the Max-Planck Institute of Biochemistry. We empower our clients in life science to establish biological knowledge through efficient reliable solutions and workflows that set the standard for protein analysis. We see a future world with revolutionized proteomic discovery processes open for everyone from science to decision. Tools that reveal hidden causes of diseases, ensure sustainable nutrition and provide diagnoses that enhance lives and society.

Press Contact PreOmics

Dr. Garwin Pichler
PreOmics GmbH
Phone: +49 (0) 89 2314163 0
E-Mail: info@preomics.com
Web: www.preomics.com